Index

active myocarditis 187, 188, 193, 206, 207
  definition 187
  histopathology 188
acute dilated cardiomyopathy 27, 28
acute heart failure, definition 240
acute left ventricular dysfunction 71, 72
acute myocarditis (AMC) 71–73, 77–79,
  202–205, 242, 266, 267
  clinical presentation 202
  epidemiology 202, 203
  inflammation and cytokines 72, 73
  matrix remodeling 77–79
  pathogenic mechanism 203–205
  viral infection 266, 267
adenovirus (ADV) 118, 204
β₁-adrenergic receptor (β₁-AR) 157
AMP-activated protein kinase 113
anti-ADP/ATP carrier (auto)antibodies
  (anti-ADP/ATP-abs) 160–163
anti-β₁-adrenergic receptor (auto)antibodies
  (anti-β₁-AR abs) 160–163
anti-cardiac autoimmunity 53
anti-cardiac immune response 53
anti-cardiac myosin-(auto)antibodies (anti-CM-
  abs) 160–163
anti-cardiac troponin I-(auto)antibodies
  (anti-cTnI-abs) 160–163
antigen-presenting cell (APC) 54
anti-heat shock protein (auto)antibodies
  (anti-HSP-abs) 160–163
  anti-muscarinic M2-receptor (auto)antibodies
    (anti-M2-abs) 160–163
antiviral strategy 177
apoptosis 54
autoantibodies/ receptor-autoantibodies 158
autoantibody-targeted therapy 164, 165
autoimmune heart disease 176
autoimmune myocarditis 157
Barth syndrome 99
Bcl-2 family 172
BICC Trial 273
biopsy, see endomyocardial biopsy
borderline myocarditis 187, 192, 193, 206
  definition 187
  capillary leakage, visualization 231
  cardiac antibodies 159
cardiac autoantibodies 159, 280, 281, 283
cardiac magnetic resonance (CMR) 206,
  227–233
cardiac tamponade 13
cardiomyopathy
  arrhythmogenic 91
classification scheme 91
etiology of 240
  hypertrophic 91, 103–106, 109–115
  peripartum 246
  restrictive 91
cardiotrophin-1 (CT-1) 173
Index

cardiotropic viral infection  201–217
cardiovascular mortality  164, 165
cD4+ T cell  176
cell adhesion molecule (CAM)  54, 204, 210, 212
cellular inhibitor of apoptosis 1 and 2  172
chronic active myocarditis  244
ciliary neurotrophic factor (CNTF)  173
clinical prognostic parameter  202
congenital heart disease  116
coxsackie adenovirus receptor (CAR)  53, 204
coxsackievirus B (CVB)  51–60, 118, 176, 203
cytokines  59, 60, 72–76, 171
cytokines, immunomodulation  59, 60
cytokines, proinflammatory  171
cytopathic effect  53, 204
cytoskeleton  92
cytotoxic T lymphocyte (CTL)  54, 204, 208
Dallas classification  187–189
Dallas criteria  123, 206, 209, 241
Danon's disease  113
decay-accelerating factor (DAF)  53
digital image analysis (DIA)  210
chronic  71–73, 77–79, 268–272
epidemiology  202, 203
final common pathway  98
incidence  202
inflammation and cytokines  72, 73
inherited  96
survival rate  202
viral infection  266–272
dystrophin  98
encephalomyocarditis virus (EMCV)  175
endomyocardial biopsy (EMB)  31, 32, 122, 187–195, 202, 206–217, 227, 228
Dallas classification  187
sensitivity of  189, 190, 192
enteroviral protease 2A  177
enterovirus (EV)  118, 203
eosinophilic myocarditis  246
Epstein-Barr virus (EBV)  204
experimental autoimmune myocarditis (EAM)  37–41
extracellular matrix (ECM)  54, 73–79
ECM remodeling  54, 74, 76–79
Fabry's disease  112
familial HCM (FHC)  105, 106, 109
Fcy receptor IIa  285
fibrosis, visualization  232
fulminant myocarditis  204, 242, 243
 genetic predisposition  158
giant cell myocarditis  29, 130, 244
heart failure  76
heat shock protein (HSP)  172
histological evaluation of myocarditis  209
histopathology  25, 188
HIV-related myocarditis  248
human herpes virus type 6 (HHV6)  204
humoral immune system  279, 280
humoral immunity  158
humoral response  59
hyperemia, visualization  231
hypersensitivity myocarditis  246
hypertrophic cardiomyopathy (HCM)  91, 103–106, 109–115
HCM, familial (FHC)  105, 106, 109
IL-6  174
IL-18  174
immune response, anti-cardiac  53
immune response, humoral antiviral  54
immunoadsorption  164, 165, 250, 281–284, 286
immunoadsorption therapy  250
immunoglobulin, intravenous  249
immunohistochemistry  189–192
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunohistological diagnosis</td>
<td>207–213</td>
</tr>
<tr>
<td>Immunomodulation, antiviral</td>
<td>57</td>
</tr>
<tr>
<td>Immunosuppression</td>
<td>58</td>
</tr>
<tr>
<td>Immunosuppressive treatment</td>
<td>248, 258–261</td>
</tr>
<tr>
<td>Infiltrate</td>
<td>204, 208–210</td>
</tr>
<tr>
<td>Inflammatory cardiomyopathy (DCMi)</td>
<td>37, 77–79, 201–217</td>
</tr>
<tr>
<td>definition</td>
<td>201</td>
</tr>
<tr>
<td>matrix remodeling</td>
<td>77–79</td>
</tr>
<tr>
<td>Pathogenic mechanism</td>
<td>203–206</td>
</tr>
<tr>
<td>Immunohistological evaluation</td>
<td>209</td>
</tr>
<tr>
<td>Inflammatory cell</td>
<td>188–190</td>
</tr>
<tr>
<td>Antibodies</td>
<td>190</td>
</tr>
<tr>
<td>Quantification on tissue</td>
<td>188</td>
</tr>
<tr>
<td>Innate immune system</td>
<td>60</td>
</tr>
<tr>
<td>Innate immunity</td>
<td>54, 60</td>
</tr>
<tr>
<td>Innate stress response</td>
<td>175</td>
</tr>
<tr>
<td>Intercalated disc</td>
<td>92</td>
</tr>
<tr>
<td>Interferon-β treatment</td>
<td>265–273</td>
</tr>
<tr>
<td>Internal cardioverter-defibrillator (ICD)</td>
<td>110</td>
</tr>
<tr>
<td>Kearns-Sayre syndrome</td>
<td>115</td>
</tr>
<tr>
<td>Left ventricular ejection fraction</td>
<td>174</td>
</tr>
<tr>
<td>Left ventricular noncompaction</td>
<td>91, 115–118</td>
</tr>
<tr>
<td>Leukemia inhibitory factor (LIF)</td>
<td>173</td>
</tr>
<tr>
<td>LPS-induced myocardial dysfunction</td>
<td>174</td>
</tr>
<tr>
<td>Lyme myocarditis</td>
<td>247</td>
</tr>
<tr>
<td>Macrophage</td>
<td>208</td>
</tr>
<tr>
<td>Magnetic resonance imaging (MRI)</td>
<td>32, 227</td>
</tr>
<tr>
<td>Manganese superoxide dismutase (MnSOD)</td>
<td>172</td>
</tr>
<tr>
<td>MERRF syndrome</td>
<td>115</td>
</tr>
<tr>
<td>Metalloproteinase</td>
<td>54</td>
</tr>
<tr>
<td>Mitochondrial cardiomyopathy</td>
<td>114</td>
</tr>
<tr>
<td>Mitogen-activated protein kinase (MAPK)-dependent pathway</td>
<td>173</td>
</tr>
<tr>
<td>Molecular mimicry</td>
<td>53</td>
</tr>
<tr>
<td>Murine myocarditis</td>
<td>37–41, 51–60, 72</td>
</tr>
<tr>
<td>Autoimmune</td>
<td>37–41</td>
</tr>
<tr>
<td>Experimental</td>
<td>72</td>
</tr>
<tr>
<td>Active</td>
<td>187, 188, 193</td>
</tr>
<tr>
<td>Borderline</td>
<td>30, 187, 192, 193</td>
</tr>
<tr>
<td>Clinical manifestation</td>
<td>27</td>
</tr>
<tr>
<td>Cardiac magnetic resonance</td>
<td>228–233</td>
</tr>
<tr>
<td>CVB-induced</td>
<td>51–60, 176</td>
</tr>
<tr>
<td>Diagnosis</td>
<td>257, 258</td>
</tr>
<tr>
<td>Giant cell</td>
<td>29</td>
</tr>
<tr>
<td>Lymphocytic</td>
<td>188</td>
</tr>
<tr>
<td>Magnetic resonance imaging</td>
<td>32</td>
</tr>
<tr>
<td>Mortality rate</td>
<td>257</td>
</tr>
<tr>
<td>Natural history</td>
<td>28</td>
</tr>
<tr>
<td>Outcome predictor</td>
<td>29, 30</td>
</tr>
<tr>
<td>Pathologic finding</td>
<td>26</td>
</tr>
<tr>
<td>Sampling error</td>
<td>26</td>
</tr>
<tr>
<td>Viral</td>
<td>95, 173–177, 194</td>
</tr>
<tr>
<td>Myocarditis treatment trial</td>
<td>28, 177</td>
</tr>
<tr>
<td>Myocardium</td>
<td>188</td>
</tr>
<tr>
<td>Myosin</td>
<td>107, 108</td>
</tr>
<tr>
<td>Myosin-binding protein C</td>
<td>108</td>
</tr>
<tr>
<td>Natural killer (NK) cell</td>
<td>54</td>
</tr>
<tr>
<td>Necrosis, visualization</td>
<td>232</td>
</tr>
<tr>
<td>Neutral sphingomyelinase pathway</td>
<td>174</td>
</tr>
<tr>
<td>Nitric oxide (NO)</td>
<td>174</td>
</tr>
<tr>
<td>Nuclear factor-kappa B (NF-κB)</td>
<td>172</td>
</tr>
<tr>
<td>Oxidative stress</td>
<td>172</td>
</tr>
<tr>
<td>Parvovirus B19</td>
<td>118, 204</td>
</tr>
<tr>
<td>Pericardial effusion</td>
<td>10–13</td>
</tr>
<tr>
<td>Pericarditis</td>
<td>3–21</td>
</tr>
<tr>
<td>Acute</td>
<td>6–9</td>
</tr>
<tr>
<td>Autoreactive</td>
<td>20</td>
</tr>
<tr>
<td>Bacterial</td>
<td>19</td>
</tr>
<tr>
<td>Chronic</td>
<td>7, 9–16</td>
</tr>
<tr>
<td>Constrictive</td>
<td>15, 16</td>
</tr>
<tr>
<td>Infectious</td>
<td>4</td>
</tr>
<tr>
<td>Neoplastic</td>
<td>21</td>
</tr>
<tr>
<td>Recurrent</td>
<td>9, 10</td>
</tr>
</tbody>
</table>
renal failure 19, 20
traumatic 5
tuberculous 19
viral 17
polymerase chain reaction (PCR) 125–128
Pompe’s disease 111
post-cardiac injury syndrome 20
prognostic impact 208

receptor autoantibodies 158
regulatory T cell 54
renal failure, pericarditis in 19, 20
sampling error, myocarditis 26
sarcolemma 92
sarcomere 92
signal transducer and activator of transcription (STAT)-mediated signaling pathway 173
small pox vaccine-related myocarditis 248
STAT3 174
T cell 39, 40, 53, 54
T cell receptor 54
T cell response 53
T lymphocyte 208
therapy, (auto)antibody-directed 164, 165
thick filament protein 107, 108
thin filament protein 108–115
toll-like receptor 54
traumatic pericardial effusion 21
tumor necrosis factor (TNF) 171

viral genome 31, 213
viral load 214
viral myocarditis 95, 173–177, 194
viral pericarditis 17
viral protease 2A 177
viral replication 213
virus-host interaction
virus-induced anti-cardiac immune response 204
vitamin cocktail, in cardiac therapy 117
The PIR-Series
Progress in Inflammation Research

Homepage: www.birkhauser.ch

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:
*T Cells in Arthritis*, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
*Medicinal Fatty Acids*, J. Kremer (Editor), 1998
*Cytokines in Severe Sepsis and Septic Shock*, H. Redl, G. Schlag (Editors), 1999
*Cytokines and Pain*, L. Watkins, S. Maier (Editors), 1999
*Pain and Neurogenic Inflammation*, S.D. Brain, P. Moore (Editors), 1999
*Apoptosis and Inflammation*, J.D. Winkler (Editor), 1999
*Novel Inhibitors of Leukotrienes*, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
*Metalloproteinases as Targets for Anti-Inflammatory Drugs*, K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
*Gene Therapy in Inflammatory Diseases*, C.H. Evans, P. Robbins (Editors), 2000
*Cellular Mechanisms in Airways Inflammation*, C. Page, K. Banner, D. Spina (Editors), 2000
*Inflammatory and Infectious Basis of Atherosclerosis*, J.L. Mehta (Editor), 2001
*Inflammation and Stroke*, G.Z. Feuerstein (Editor), 2001
*NMDA Antagonists as Potential Analgesic Drugs*, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002
*Mechanisms and Mediators of Neuropathic pain*, A.B. Malmberg, S.R. Chaplan (Editors), 2002
*Bone Morphogenetic Proteins. From Laboratory to Clinical Practice*, S. Vukicevic, K.T. Sampath (Editors), 2002
*The Hereditary Basis of Allergic Diseases*, J. Holloway, S. Holgate (Editors), 2002
*Inflammation and Cardiac Diseases*, G.Z. Feuerstein, P. Libby, D.L. Mann (Editors), 2003
*Mind over Matter – Regulation of Peripheral Inflammation by the CNS*, M. Schäfer, C. Stein (Editors), 2003
*Heat Shock Proteins and Inflammation*, W. van Eden (Editor), 2003
*Pharmacotherapy of Gastrointestinal Inflammation*, A. Guglietta (Editor), 2004
*Arachidonate Remodeling and Inflammation*, A.N. Fonteh, R.L. Wykle (Editors), 2004
*Recent Advances in Pathophysiology of COPD*, P.J. Barnes, T.T. Hansel (Editors), 2004
*Cytokines and Joint Injury*, W.B. van den Berg, P. Miossec (Editors), 2004